138 related articles for article (PubMed ID: 11318154)
21. Flexible designs by adaptive plans of generalized Pocock- and O'Brien-Fleming-type and by self-designing clinical trials.
Hartung J
Biom J; 2006 Aug; 48(4):521-36. PubMed ID: 16972703
[TBL] [Abstract][Full Text] [Related]
22. Power and sample size calculation incorporating misspecifications of the variance function in comparative clinical trials with over-dispersed count data.
Igeta M; Takahashi K; Matsui S
Biometrics; 2018 Dec; 74(4):1459-1467. PubMed ID: 29579337
[TBL] [Abstract][Full Text] [Related]
23. Adaptive group sequential test for clinical trials with changing patient population.
Feng H; Shao J; Chow SC
J Biopharm Stat; 2007; 17(6):1227-38. PubMed ID: 18027228
[TBL] [Abstract][Full Text] [Related]
24. Information-based sample size re-estimation in group sequential design for longitudinal trials.
Zhou J; Adewale A; Shentu Y; Liu J; Anderson K
Stat Med; 2014 Sep; 33(22):3801-14. PubMed ID: 24797715
[TBL] [Abstract][Full Text] [Related]
25. Conditional estimation using prior information in 2-stage group sequential designs assuming asymptotic normality when the trial terminated early.
Shimura M; Maruo K; Gosho M
Pharm Stat; 2018 Sep; 17(5):400-413. PubMed ID: 29687592
[TBL] [Abstract][Full Text] [Related]
26. Implementing type I & type II error spending for two-sided group sequential designs.
Rudser KD; Emerson SS
Contemp Clin Trials; 2008 May; 29(3):351-8. PubMed ID: 17933592
[TBL] [Abstract][Full Text] [Related]
27. Stopping boundaries adjusted for sample size reestimation and negative stop.
Shun Z
J Biopharm Stat; 2002 Nov; 12(4):485-502. PubMed ID: 12477071
[TBL] [Abstract][Full Text] [Related]
28. A Bayesian predictive sample size selection design for single-arm exploratory clinical trials.
Teramukai S; Daimon T; Zohar S
Stat Med; 2012 Dec; 31(30):4243-54. PubMed ID: 22807115
[TBL] [Abstract][Full Text] [Related]
29. Planning and analyzing adaptive group sequential survival trials.
Wassmer G
Biom J; 2006 Aug; 48(4):714-29. PubMed ID: 16972724
[TBL] [Abstract][Full Text] [Related]
30. Standard versus adaptive monitoring procedures: A commentary.
Fleming TR
Stat Med; 2006 Oct; 25(19):3305-12; discussion 3313-4, 3326-47. PubMed ID: 16850447
[TBL] [Abstract][Full Text] [Related]
31. Design considerations in crossover trials with a single interim analysis and serial patient entry.
Cook RJ; Willan AR
Biometrics; 1996 Jun; 52(2):732-9. PubMed ID: 8672709
[TBL] [Abstract][Full Text] [Related]
32. A review of methods for futility stopping based on conditional power.
Lachin JM
Stat Med; 2005 Sep; 24(18):2747-64. PubMed ID: 16134130
[TBL] [Abstract][Full Text] [Related]
33. On efficient two-stage adaptive designs for clinical trials with sample size adjustment.
Liu Q; Li G; Anderson KM; Lim P
J Biopharm Stat; 2012; 22(4):617-40. PubMed ID: 22651105
[TBL] [Abstract][Full Text] [Related]
34. Sample size re-estimation in group-sequential response-adaptive clinical trials.
Morgan CC
Stat Med; 2003 Dec; 22(24):3843-57. PubMed ID: 14673942
[TBL] [Abstract][Full Text] [Related]
35. A practical comparison of group-sequential and adaptive designs.
Kelly PJ; Sooriyarachchi MR; Stallard N; Todd S
J Biopharm Stat; 2005; 15(4):719-38. PubMed ID: 16022175
[TBL] [Abstract][Full Text] [Related]
36. A self-designing rule for clinical trials with arbitrary response variables.
Hartung J
Control Clin Trials; 2001 Apr; 22(2):111-6. PubMed ID: 11306149
[TBL] [Abstract][Full Text] [Related]
37. Sample size adaptation in fixed-dose combination drug trial.
James Hung HM; Wang SJ
J Biopharm Stat; 2012; 22(4):679-86. PubMed ID: 22651108
[TBL] [Abstract][Full Text] [Related]
38. Flexible two-stage design with sample size reassessment for survival trials.
Desseaux K; Porcher R
Stat Med; 2007 Nov; 26(27):5002-13. PubMed ID: 17577242
[TBL] [Abstract][Full Text] [Related]
39. Optimization of adaptive designs: efficiency evaluation.
Menon S; Chang M
J Biopharm Stat; 2012; 22(4):641-61. PubMed ID: 22651106
[TBL] [Abstract][Full Text] [Related]
40. Group sequential tests for bivariate response: interim analyses of clinical trials with both efficacy and safety endpoints.
Jennison C; Turnbull BW
Biometrics; 1993 Sep; 49(3):741-52. PubMed ID: 8241370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
